ArticleJournal of vascular surgery cases and innovative techniques2026
Fenestrated endovascular aneurysm repair addressing para-aortic ulcers in the setting of tuberculous aortitis.
Article in Journal of vascular surgery cases and innovative techniques, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Fenestrated endovascular aneurysm repair (FEVAR) has become a preferred approach for complex aortic pathology involving the visceral vessels, particularly in patients at high risk for open repair. Tuberculosis aortitis is rare, with few documented cases involving the visceral aorta. This case report describes a 68-year-old man with a history of bladder cancer undergoing immunotherapy who developed penetrating aortic ulcers secondary to suspected tuberculosis aortitis and underwent successful laser FEVAR. This case highlights the feasibility and efficacy of laser FEVAR for complex aortic disease such as tuberculosis aortitis and demonstrates its role as a life-saving strategy in high-risk patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.